InsidersTradesSigma
Total declarations
Companies
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
15
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by LALANDE KEVIN M., Director. Officer active across 3 companies, notably LUMOS PHARMA, INC.. Aggregated, 19 reports have been recorded. Split: 15 buys · 0 sell. Total volume traded: €2m. Activity tracked since 20 May 2021. The latest transaction was filed on 2 April 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations19 total
1,076 sharesCommon StockSEC:0001126234-24-000115:0
175,000 shares@ US$2.3581.4% of flowCommon StockSEC:0001415889-24-010303:0
100,000 shares@ US$0.91100.0% of flowCommon StockSEC:0001209191-22-038477:0
Ideal exit: 10 Mar 2023 (T+270)
10,000 shares@ US$11.211610.1% of flowCommon StockSEC:0001126234-21-000141:0
Ideal exit: 5 Jun 2022 (T+270)
10,000 shares@ US$11.211610.1% of flowCommon StockSEC:0001126234-21-000141
Ideal exit: 5 Jun 2022 (T+270)
6,300 shares@ US$11.22846.3% of flowCommon StockSEC:0001126234-21-000138:0
Ideal exit: 30 May 2022 (T+270)
6,300 shares@ US$11.22846.3% of flowCommon StockSEC:0001126234-21-000138
Ideal exit: 30 May 2022 (T+270)
8,625 shares@ US$10.52038.2% of flowCommon StockSEC:0001126234-21-000133
Ideal exit: 27 May 2022 (T+270)
8,625 shares@ US$10.52038.2% of flowCommon StockSEC:0001126234-21-000133:0
Ideal exit: 27 May 2022 (T+270)
14,900 shares@ US$9.87113.3% of flowCommon StockSEC:0001126234-21-000129
Ideal exit: 22 May 2022 (T+270)
14,900 shares@ US$9.87113.3% of flowCommon StockSEC:0001126234-21-000129:0
Ideal exit: 22 May 2022 (T+270)
35,679 shares@ US$8.734528.4% of flowCommon StockSEC:0001126234-21-000123
Ideal exit: 17 May 2022 (T+270)
35,679 shares@ US$8.734528.4% of flowCommon StockSEC:0001126234-21-000123:0
Ideal exit: 17 May 2022 (T+270)
16,000 shares@ US$8.465412.3% of flowCommon StockSEC:0001126234-21-000117:0
Ideal exit: 14 May 2022 (T+270)
16,000 shares@ US$8.465412.3% of flowCommon StockSEC:0001126234-21-000117
Ideal exit: 14 May 2022 (T+270)
31,000 shares@ US$7.546221.2% of flowCommon StockSEC:0001126234-21-000115:0
Ideal exit: 9 May 2022 (T+270)
31,000 shares@ US$7.546221.2% of flowCommon StockSEC:0001126234-21-000115
Ideal exit: 9 May 2022 (T+270)
367 shares0Common StockSEC:0001126234-21-000080
367 shares0Common StockSEC:0001126234-21-000080:0
19 of 19 declarations
About LALANDE KEVIN M.
Kevin M. Lalande is an insider at Lumos Pharma, Inc.
